Advertisement

TELA Bio, Inc. TELA

Set alert

Price alert · TELA

All alert types
0.81 USD -0.11 -11.95%

At close · Oct 30

0.81 0.00 0.00%

After hours · Oct 30, 4:40 PM ET

Bid
0.82 × 2
Ask
0.82 × 2
0.8101 Day range 0.92
0.56 52-week range 1.41
YTD
-31.35%
1 year
-37.68%
Open
0.91
Prev close
0.92
Mkt cap
36.57M
Vol
330.11K
Avg vol
228.49K
EPS
-0.77
P/E
0.00
Div yield
0.00%
More statistics
Low
0.8101
High
0.92
Forward P/E
-4.31
Beta
0.97
Short ratio
1.28
Inst. own
51.68%
Dividend
0.00
Ex-div date
Earnings
Aug 12, 2024
50-d avg
2.85
200-d avg
4.02
1y target
9.20

2Y chart

Chart tools
Interval

Events in this range
  • Nov 7, 2024Earnings: -0.42; estimate -0.37; surprise -13.51%
  • Nov 8, 2024Rating: Piper Sandler · Overweight → Overweight
Signals (71)
NameDateAgo
SMA: BearishOct 30, 20261 day ago
SMA: BearishOct 23, 20261 week ago
MACD: Sell SignalSep 30, 20261 month ago
RSI: OverboughtSep 11, 20261 month ago
SMA: BullishSep 9, 20261 month ago
SMA: BullishSep 1, 20262 months ago
MACD: Buy SignalAug 31, 20262 months ago
MACD: Sell SignalAug 13, 20262 months ago
SMA: BearishAug 11, 20262 months ago
SMA: BearishAug 11, 20262 months ago
SMA: BullishAug 10, 20262 months ago
SMA: BullishAug 4, 20262 months ago
MACD: Buy SignalJul 31, 20263 months ago
MACD: Sell SignalJul 17, 20263 months ago
SMA: BearishJul 8, 20263 months ago
SMA: BullishJul 7, 20263 months ago
MACD: Buy SignalJul 7, 20263 months ago
SMA: BearishJun 18, 20264 months ago
SMA: BullishJun 16, 20264 months ago
SMA: BearishJun 15, 20264 months ago
MACD: Sell SignalMay 15, 20265 months ago
RSI: OverboughtMay 1, 20266 months ago
SMA: BullishApr 27, 20266 months ago
MACD: Buy SignalApr 15, 20266 months ago
MACD: Sell SignalMar 25, 20267 months ago
MACD: Buy SignalMar 23, 20267 months ago
MACD: Sell SignalMar 13, 20267 months ago
MACD: Buy SignalFeb 24, 20268 months ago
RSI: OversoldFeb 20, 20268 months ago
RSI: OversoldFeb 12, 20268 months ago
RSI: OversoldFeb 4, 20268 months ago
MACD: Sell SignalFeb 3, 20269 months ago
MACD: Buy SignalJan 30, 20269 months ago
MACD: Sell SignalJan 9, 20269 months ago
MACD: Buy SignalNov 21, 202511 months ago
RSI: OversoldNov 13, 202511 months ago
RSI: OversoldOct 30, 20251 year ago
MACD: Sell SignalOct 29, 20251 year ago
MACD: Buy SignalOct 3, 20251 year ago
MACD: Sell SignalSep 25, 20251 year ago
MACD: Buy SignalSep 19, 20251 year ago
MACD: Sell SignalSep 4, 20251 year ago
MACD: Buy SignalAug 22, 20251 year ago
SMA: BearishAug 6, 20251 year ago
SMA: BullishAug 1, 20251 year ago
SMA: BearishJul 31, 20251 year ago
MACD: Sell SignalJul 11, 20251 year ago
MACD: Buy SignalJul 9, 20251 year ago
MACD: Sell SignalJul 7, 20251 year ago
MACD: Buy SignalJun 27, 20251 year ago
MACD: Sell SignalJun 16, 20251 year ago
RSI: OverboughtJun 3, 20251 year ago
RSI: OverboughtMay 27, 20251 year ago
RSI: OverboughtMay 22, 20251 year ago
SMA: BullishMay 20, 20251 year ago
MACD: Buy SignalApr 14, 20251 year ago
MACD: Sell SignalMar 21, 20251 year ago
RSI: OversoldMar 21, 20251 year ago
MACD: Buy SignalMar 18, 20251 year ago
MACD: Sell SignalFeb 26, 20251 year ago
SMA: BearishFeb 21, 20251 year ago
SMA: BullishFeb 19, 20251 year ago
MACD: Buy SignalFeb 18, 20251 year ago
MACD: Sell SignalFeb 12, 20251 year ago
MACD: Buy SignalFeb 3, 20251 year ago
MACD: Sell SignalJan 31, 20251 year ago
MACD: Buy SignalJan 29, 20251 year ago
MACD: Sell SignalJan 10, 20251 year ago
MACD: Buy SignalJan 8, 20251 year ago
MACD: Sell SignalJan 7, 20251 year ago
MACD: Buy SignalDec 26, 20241 year ago

Key statistics

Market cap
115.41M
Enterprise value
95.57M
Trailing P/E
0.00
Forward P/E
-4.31
PEG ratio
0.00
Price / sales
1.68
Price / book
0.00
EPS (TTM)
-1.69
Beta
0.97
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-60.49%
Revenue (TTM)
68.65M
Revenue growth
25.90%
Free cash flow
0
Total cash
17.30M
Total debt
42.43M
Return on equity
-342.04%
Shares outstanding
39.39M
Short % of float
0.98%
50-day average
2.85
200-day average
4.02

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 9.20 +1035.7% upside
Target (low)
5.00
Target (mean)
9.20
Target (high)
12.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
  • Strong buy2
  • Buy3
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Aug 12, 2024

Expected Aug 12, 2024. Consensus EPS estimate -0.222.

Earnings history

Financials — quick view

All financials
TELA Revenue — quarterly 19.29M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
TELA Net income — quarterly -11.26M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
TELA EPS — quarterly -0.20
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

TELA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 2024-0.37-0.42-0.05-13.51%
Aug 12, 2024Jun 1, 2024-0.45-0.51-0.06-13.33%
Aug 12, 2024Jun 1, 2024-0.45———
May 9, 2024Mar 1, 2024-0.48———
May 9, 2024Mar 1, 2024-0.48-0.23+0.25+52.08%
Mar 21, 2024Dec 1, 2023-0.44-0.53-0.09-20.45%

Upgrades / downgrades

TELA analyst upgrades and downgrades
DateFirmActionFromTo
Nov 8, 2024Piper SandlermainOverweightOverweight
Oct 4, 2024Canaccord GenuitymainBuyBuy
Aug 13, 2024Lake StreetmainBuyBuy
Aug 13, 2024Canaccord GenuitymainBuyBuy
Aug 13, 2024JMP SecuritiesmainMarket OutperformMarket Outperform
Aug 13, 2024Piper SandlermainOverweightOverweight

About TELA Bio, Inc.

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
telabio.com

News

Your note

Sign in to keep a note on TELA — it syncs with the Stock Master app.

Insider holders

TELA insider holders
InsiderRelationLatest transactionDateShares held
AZARBARZIN KURTDirectorStock Award(Grant)Jun 3, 202410,520
BURGESS VINCENT JDirectorStock Award(Grant)Jun 3, 202415,380
COLLERAN LISA NDirectorStock Award(Grant)Jun 3, 202410,520
CUCA ROBERTOChief Operating OfficerPurchaseOct 23, 2024155,388
EVANS DOUGLAS GDirectorStock Award(Grant)Jun 3, 202410,520
FIRESTONE GREGORY AOfficerPurchaseOct 23, 202457,279

Institution ownership

TELA institution ownership
Holder% heldSharesValueReported
Essex Woodlands Management Inc.10.44%4,110,70912.04MSep 29, 2024
AIGH Capital Management LLC6.27%2,469,3737.24MSep 29, 2024
Orbimed Advisors LLC.5.49%2,161,1856.33MSep 29, 2024
Nantahala Capital Management, LLC4.86%1,915,1265.61MSep 29, 2024
SilverArc Capital Management, LLC2.86%1,124,9283.30MSep 29, 2024
Stonepine Capital Management, LLC2.82%1,110,0003.25MSep 29, 2024

Fund ownership

TELA fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.63%643,2901.88MSep 29, 2024
Vanguard Extended Market Index Fund0.58%226,799664.52KSep 29, 2024
Federated Hermes Kaufmann Fund0.39%153,969451.13KJul 30, 2024
Jacob Discovery Fd0.35%139,775409.54KOct 30, 2024
Bridgeway Funds Inc-Ultra Small Company Market Fund0.26%101,000295.93KSep 29, 2024
Fidelity Extended Market Index Fund0.21%81,201237.92KOct 30, 2024
Advertisement